Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
NOT YET RECRUITING
NCT05750589
PHASE3
Safety and Tolerability of IRX-101 in Patients Receiving Intravitreal Injections
Sponsor: iRenix Medical, Inc.
View on ClinicalTrials.gov
Summary
This is a randomized, double-masked study to evaluate the tolerability and safety of IRX-101 versus 5% povidone-iodine (PI) in subjects receiving intravitreal anti-VEGF injections.
Official title: Randomized, Controlled, Double-Masked Study to Evaluate the Efficacy of IRX-101 in Reducing Post-Intravitreal Pain and Corneal Epitheliopathy
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
240
Start Date
2026-09-01
Completion Date
2027-12-31
Last Updated
2026-04-03
Healthy Volunteers
Yes
Conditions
Interventions
DRUG
IRX-101
IRX-101 is a novel ocular anti-septic
DRUG
Providone-Iodine
5% Providone-Iodine
Locations (1)
R. Gary Lane, II MD
San Antonio, Texas, United States